Appendix Correction Issued for the 2025 Endometrial Carcinoma Guideline Update
Lancet Oncology has corrected the appendix to its 2025 Policy Review on the ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma. The update applies to the article by Concin N, Matias-Guiu X, Cibula D, and colleagues, published in 2025 as volume 26, pages e423–35. The correction was made to the appendix of the Policy Review and recorded as of Oct 26, 2026.
Even a correction confined to supplementary material matters in oncology guideline work. Appendices often carry the operational details that clinicians, tumor boards, and multidisciplinary teams use to translate broad recommendations into practice: staging clarifications, treatment algorithms, evidence summaries, and implementation notes. When those details are revised, the core clinical message may remain intact, but the precision behind the recommendation changes. In a disease such as endometrial carcinoma, where risk stratification and treatment selection depend on fine distinctions in histology, stage, and molecular context, the margin for ambiguity is small.
The correction notice itself does not specify which appendix elements were amended. It does, however, confirm that the published guideline package required an update after release. In the context of a major international policy review, that is not a trivial editorial event. Guidelines in oncology are often used as reference points across health systems, and even small textual or tabular changes can alter how physicians interpret eligibility for surgery, radiotherapy, systemic therapy, or follow-up pathways.
One sentence carries the practical weight of the notice: the appendix changed after publication.
For clinicians managing patients with endometrial carcinoma, the implication is straightforward. The main article should still be read as the primary guide, but any decision drawn from the 2025 update now needs to be checked against the corrected appendix version. That is especially relevant for teams that rely on supplementary tables for dosing, classification, or sequencing details rather than reading the narrative recommendations alone. In oncology, those supplemental materials often become the working document inside the clinic.
Guideline corrections also reflect the reality of high-stakes consensus writing. Large expert panels synthesize evolving evidence, reconcile differences in interpretation, and convert trial data into usable recommendations. The appendix is where much of that technical labor becomes visible. If a correction is issued, the responsible course for clinicians and institutions is to use the revised version and ensure that local protocols, order sets, and teaching materials align with it.
The notice does not identify any patient harm, any change in the central recommendations, or any alteration to the overall scope of the Policy Review. It simply establishes that the appendix has been corrected. That limited wording keeps the scope of interpretation appropriately narrow. Without the amended appendix text, no further conclusions can be drawn about the nature or clinical direction of the revision.
Still, the correction serves as a reminder that oncology guidance is a living document. Endometrial cancer management has become increasingly dependent on nuanced interpretation of pathology and stage, with care often coordinated among gynecologic oncologists, radiation oncologists, medical oncologists, and pathologists. A corrected appendix may affect how that coordination is documented or operationalized, even when the headline recommendation remains unchanged.
For readers using the 2025 update in practice, the safest interpretation is procedural: consult the corrected version before citing the guideline, building local pathways, or teaching the document to trainees. In academic medicine, appendix-level revisions can travel quickly into slide decks, care pathways, and institutional protocols. A correction notice is the mechanism that keeps that downstream use tethered to the most current version of the evidence summary.
Why a Supplementary Correction Still Matters in Oncology Practice
The value of a correction in a guideline paper lies in precision. Endometrial carcinoma is not a disease category that tolerates casual interpretation, and the same is true of the documents that shape its management. An appendix may hold the detail that decides whether a recommendation is applied correctly, especially when clinicians are working from condensed summaries rather than the full article.
This correction notice does not expand into methodologic critique, nor does it announce a change in the core conclusions of the policy review. Its message is narrower: the appendix was corrected after publication. That narrowness is itself important. It signals editorial transparency and gives clinicians a clear instruction to use the revised material.
In daily oncology practice, this kind of update is easy to miss and difficult to ignore. It can affect citations, institutional guideline committees, resident education, and the interpretation of treatment algorithms embedded in the supplementary files. When a policy review is as influential as an ESGO–ESTRO–ESP guideline update, the corrected appendix becomes part of the active clinical record.
What Clinicians Should Verify Before Using the 2025 Update
The public notice does not identify the amended appendix section, so no attempt should be made to infer which recommendation changed. The only defensible action is verification. Clinicians and departments using the 2025 update should check the corrected appendix version before incorporating its content into local practice documents or educational material.
For multidisciplinary teams, that may mean rechecking the supplementary tables attached to the guideline before tumor board discussion, protocol revision, or manuscript preparation. For researchers and guideline authors, it means citing the corrected version rather than the unamended appendix. For trainees, it means recognizing that supplementary material is not disposable background; in oncology, it can contain the details that make the recommendation usable at the bedside.
The correction closes one gap in the published record, but it also leaves an obvious question unanswered: what exactly changed in the appendix? Until the amended text is reviewed directly, the clinical meaning of the correction remains bounded to the fact of revision itself. In guideline medicine, that is often enough to justify a fresh look before the document is used again.